Program
CD137/Nectin-4 Bispecific-targeting Agent BT7480
Its studies are led by BicycleTx.
Furthest: phase 2, since Nov 19, 20212 company-led studies, 2 open or runningNext primary completion: May 30, 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BicycleTx | 22 open or running | phase 2since Nov 19, 2021 | Nov 19, 2021 | May 30, 2030phase 2 · NCT07681674 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2021First study: phase 2 study in Advanced Solid TumorFirst studyNCT05163041 · 200 enrolled · United States, United Kingdom
- Jun 26, 2026Phase 2 study in Advanced Solid TumorsNCT07681674 · 16 planned
Ahead
- May 30, 2030Primary completion: phase 2 study in Advanced Solid TumorsNCT07681674
TargetBeta
TNFRSF9 →read by rule
“A synthetic tumor targeted immune cell agonist composed of two bicyclic peptides targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) ”NCIt, by rule
Other programs on TNFRSF9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| Anti-CD137 Agonistic Monoclonal Antibody CTX-471rule | compass-therapeutics | phase 2 | 2 |
| Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314rule | BioNTech | phase 2 | 2 |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | abl-bio-inc | phase 2 | 2 |
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 2 |
| Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| LM-2417 | Sino Biopharmaceutical | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Anti-CD137/PD-L1 Bispecific Antibody FS222 | Sino Biopharmaceutical | phase 1 | 1 |
| Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015rule | medigene-ag | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07681674Advanced Solid Tumors | 2 | Not yet recruiting | May 30, 2030 | 16 |
| NCT05163041Advanced Solid Tumor · United States, United Kingdom | 2 | Active, not recruiting | Aug 2026 | 200 |
How it is read
Names in the registry
- “BT7480”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.